Three Emerging Trends For China’s Pharmaceutical Foreign Trade
This article was originally published in PharmAsia News
With the global economic slowdown, China's pharmaceutical foreign trade is likely to face its most difficult year yet since the beginning of the new century. In 2009, three development trends are emerging: (1) growth is expected to continue, with China maintaining its advantage and global market share in drug raw materials, especially antibiotics, vitamins, antipyretic analgesics and amino acids; (2) medical imports and exports will balance out health care reform resulting in increased domestic demand that will increase import volumes for major medical devices, technology, Western medicine and biomedicine, with high-end medical device import growth expected to hit double digits; and (3) many barriers will be encountered due to the rising yuan and intensifying trade war against China-made products. (Click here for more - Chinese Language)
You may also be interested in...
Gilead's remdesivir is first drug fully approved by FDA to treat COVID-19. Roche and Atea team up on an investigational direct acting antiviral while Moderna reaches the 30,000-patient enrollment target for its Phase III COVE study of the company's investigational mRNA vaccine.
From efficacy endpoints to patient warehousing, US FDA advisors weigh in on vaccine development and regulatory review.
Several years ago, heart device giant Edwards Lifesciences realized it needed a new CAPA framework that shifts corrective and preventive action from a one-size-fits-all method to a more nuanced approach. See what Dan Buehner, director of quality engineering at Edwards Lifesciences, said about it here.